Funding Success: Unlearn Revolutionizes Clinical Trials with Digital Twin Tech

TLDR: AI company Unlearn has secured $50m in a Series C funding round led by Altimeter Capital, for optimising clinical research with digital twin technology. The funding round saw participation from returning investors namely Wittington Ventures, Radical Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital. Unlearn will use the investment to advance its mission of using AI to reduce trial and error in medicine by investing in its workforce, data, engineering expertise, and lasting research and development approaches. Since its inception in 2017, Unlearn has secured more than $130m for developing AI solutions that create digital twins for trial participants, leading to smaller, quicker studies. Its technology is designed to tackle challenges associated with clinical research, such as extended timelines, sluggish enrollment, and reluctance of patients due to the possibility of receiving a placebo.